PDPN and glioma: Furthermore, the risk of VTE in podoplanin expressing high-grade glioma was significantly higher compared to podoplanin-negative high-grade glioma (hazard ratio = 3.44; 95% confidence interval, 1.19–9.95; p = 0.022), and podoplanin expression in these patients was also associated with a higher mortality [33].